Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
48
CNMD Quote, Financials, Valuation and Earnings
Last price:
$46.02
Seasonality move
:
3.67%
Day range:
$45.72 - $47.08
52-week range:
$35.37 - $64.87
Dividend yield:
1.74%
P/E ratio:
30.28x
P/S ratio:
1.04x
P/B ratio:
1.37x
Volume:
517.4K
Avg. volume:
617K
1-year change:
-25.32%
Market cap:
$1.4B
Revenue:
$1.4B
EPS (TTM):
$1.52
Analysts' Opinion
-
Consensus RatingCONMED Corp. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $47.40, CONMED Corp. has an estimated upside of 3.34% from its current price of $45.87.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $42.00 representing 100% downside risk from its current price of $45.87.
Fair Value
-
According to the consensus of 5 analysts, CONMED Corp. has 3.34% upside to fair value with a price target of $47.40 per share.
CNMD vs. S&P 500
-
Over the past 5 trading days, CONMED Corp. has overperformed the S&P 500 by 2.93% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
CONMED Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CONMED Corp. has grown year-over-year revenues for 12 quarters straight. In the most recent quarter CONMED Corp. reported revenues of $373.5M.
Earnings Growth
-
CONMED Corp. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter CONMED Corp. reported earnings per share of $0.54.
Enterprise value:
2.3B
EV / Invested capital:
1.18x
Price / LTM sales:
1.04x
EV / EBIT:
16.21x
EV / Revenue:
1.65x
PEG ratio (5yr expected):
0.99x
EV / Free cash flow:
14.99x
Price / Operating cash flow:
9.45x
Enterprise value / EBITDA:
11.45x
Gross Profit (TTM):
$719.7M
Return On Assets:
2.03%
Net Income Margin (TTM):
3.42%
Return On Equity:
4.72%
Return On Invested Capital:
2.49%
Operating Margin:
17.91%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $1.2B | $1.3B | $1.4B | $343.9M | $373.5M | |
| Gross Profit | $629.5M | $687.8M | $719.7M | $182.8M | $213.3M | |
| Operating Income | $113.2M | $172.1M | $139.5M | $53.8M | $66.9M | |
| EBITDA | $169.6M | $228.5M | $197.5M | $71.8M | $85.7M | |
| Diluted EPS | $2.04 | $4.25 | $1.52 | $1.08 | $0.54 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $460.1M | $581.2M | $615.6M | $640M | $672.9M | |
| Total Assets | $1.8B | $2.3B | $2.3B | $2.3B | $2.3B | |
| Current Liabilities | $196.6M | $296.6M | $310.7M | $278.1M | $315M | |
| Total Liabilities | $980.6M | $1.6B | $1.5B | $1.3B | $1.3B | |
| Total Equity | $785.4M | $745.5M | $834.2M | $962.7M | $1B | |
| Total Debt | $684.7M | $1.1B | $983.7M | $939.1M | $878.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $125.3M | $167M | $170.7M | $43.3M | $46.3M | |
| Cash From Investing | -$20M | -$13.1M | -$21M | -$4M | -$7.1M | |
| Cash From Financing | -$110.4M | -$151M | -$135.8M | -$51.1M | -$37.4M | |
| Free Cash Flow | $106.3M | $153.9M | $150.9M | $39.3M | $41.2M | |
CNMD
Sector
Market Cap
$1.4B
$25.8M
Price % of 52-Week High
70.71%
50.24%
Dividend Yield
1.74%
0%
Shareholder Yield
2.82%
-1.64%
1-Year Price Total Return
-25.32%
-18.88%
Beta (5-Year)
0.967
0.496
Dividend yield:
1.74%
Annualized payout:
$0.60
Payout ratio:
217.16%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$44.97
200-day SMA
Sell
Level
$48.04
Bollinger Bands (100)
Buy
Level
40.28 - 45.48
Chaikin Money Flow
Buy
Level
2.9M
20-day SMA
Buy
Level
$42.29
Relative Strength Index (RSI14)
Buy
Level
67.86
ADX Line
Buy
Level
35.31
Williams %R
Sell
Level
-17.5097
50-day SMA
Buy
Level
$41.62
MACD (12, 26)
Buy
Level
8.72
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
4M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.9139)
Buy
CA Score
(Annual)
Level (-0.2751)
Buy
Beneish M-Score
(Annual)
Level (-2.7139)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.1528)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CONMED Corp. is a medical technology company, which engages in providing devices and equipment for surgical procedures. Its products include AirSeal and insufflation, allograft cartilage and tissue, arthroplasty, biliary and endoscopic ultrasound, biomedical sensors and electrodes, biopsy and polypectomy, dilators and accessories, electrosurgical units, fixation devices, hemostasis, implants and suture anchors, infection prevention, patient positioning, and related products. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.
Stock Forecast FAQ
In the current month, CNMD has received 0 Buy ratings 5 Hold ratings, and 0 Sell ratings. The CNMD average analyst price target in the past 3 months is $47.40.
-
Where Will CONMED Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that CONMED Corp. share price will rise to $47.40 per share over the next 12 months.
-
What Do Analysts Say About CONMED Corp.?
Analysts are divided on their view about CONMED Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CONMED Corp. is a Sell and believe this share price will drop from its current level to $42.00.
-
What Is CONMED Corp.'s Price Target?
The price target for CONMED Corp. over the next 1-year time period is forecast to be $47.40 according to 5 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is CNMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CONMED Corp. is a Hold. 5 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CNMD?
You can purchase shares of CONMED Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CONMED Corp. shares.
-
What Is The CONMED Corp. Share Price Today?
CONMED Corp. was last trading at $46.02 per share. This represents the most recent stock quote for CONMED Corp.. Yesterday, CONMED Corp. closed at $45.87 per share.
-
How To Buy CONMED Corp. Stock Online?
In order to purchase CONMED Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CNMD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CNMD
Sector
P/E ratio
30.28x
23.44x
PEG ratio
0.99x
-0.01x
P/B ratio
1.37x
1.81x
Price / LTM sales
1.04x
1.56x
Growth Metrics
CNMD
Sector
Revenue growth
8.59%
3.27%
Earnings growth
-50.23%
9.66%
Revenue (5-year growth)
9.82%
6.43%
Earnings forecast
$1.32
-$0.20
Profitability
CNMD
Sector
Profitability FY 2025
$725.4M
$2.3M
Return on invested capital
2.49%
-33.49%
Return on assets
2.03%
-29.74%
Return on equity
4.72%
-39.33%
Earnings Date
Last Earnings Date
Jan
28
Next Earnings Date
Apr
29
Estimated Next Earnings Date
Apr
29
Balance Sheet
CNMD
Sector
Total cash
$40.8M
$24.2M
Short term investments
--
$23.8M
Total assets
$2.3B
$71.1M
Long term debt
$878.9M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
